Table 1.
Cytotoxicity (IC50) of compounds and ADC toward cancer cell lines.
| Cell line | IC50 (nmol/L)/Maximal inhibition ratio |
Cell line | HER2 level§ | IC50 (nmol/L)/Maximal inhibition ratio |
||||
|---|---|---|---|---|---|---|---|---|
| MF-6 | DXd | SN38 | MF-6 | TS | TS-L6 | |||
| BT474 | 6.84/72.1% | 15.62/71.7% | 36.26/72.4% | BT474 | 186.1 | 1.02#/80.7% | 0.54/81.6% | 0.50/67.0% |
| NCI-N87 | 0.66/91.7% | 7.81/88/3% | 4.50/87.8% | NCI-N87 | 524.5 | 0.17/98.5% | 0.23/46.9% | 0.24/66.6% |
| SK-BR-3 | 1.38/89.0% | 6.33/85.7% | 5.57/87.6% | SK-BR-3 | 171.6 | 0.59/98.4% | 0.33/51.7% | 0.37/54.3% |
| BxPC-3 | 0.72/96.5% | 15.46/98.9% | 5.25/98.3% | CT26.WT-HER2 | 60.6 | 3.25/95.5% | N/A* | N/A |
§ :The relative HER2 expression level was calculated as the ratio of mean fluorescence intensity of positive group with primary HER2 antibody added to the negative control group with fluorescence-labeled secondary antibody only.
# :The differences between two results of MF-6 on BT474, NCI-N87 and SK-BR-3 were due to the different cytotoxicity evaluation condition in two studies, such as cell number and incubation time.
* :No significant cell growth inhibition.